Skip to main content
OpenTrials
Withdrawn

NCT Number: NCT00368381

Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis

The purpose of this study is to determine if the combination of hydrocortisone plus fludrocortisone is more efficacious than hydrocortisone alone in treating adrenal insufficiency in severe sepsis.

Why the study stopped: Study closed for PI failure to submit renewal paperwork
Withdrawn

Looking for future studies?

Notify Me

Key information

About this study

Sepsis is a significant cause of morbidity and mortality in critically ill patients in the United States. As evidenced by its increasing prevalence and high mortality rates, sepsis is a complex and difficult syndrome to treat. Current therapeutic management of sepsis includes fluid resuscitation, vasopressor and inotropic support, maintenance of oxygen delivery, drotrecogin alpha, and steroid replacement therapy in patients who are found to have adrenal insufficiency. Studies in septic patients suggest that the administration of stress doses of hydrocortisone alone, or the combination of hydrocortisone plus fludrocortisone promotes an improvement in cardiovascular performance and a quicker resolution of shock symptoms. Current therapeutic guidelines for the treatment of severe sepsis recommend either hydrocortisone alone or combination therapy with hydrocortisone and fludrocortisone as therapeutic options for the treatment of adrenal dysfunction in severe sepsis. This study will help determine which regimen is more efficacious in this patient population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and non-pregnant females > 18 years of age
  • Patients admitted and/or pending admission to the intensive care unit
  • Positive corticotropin stimulation test (Basal cortisol level of ≤ 34 μg/dL with Δ ≤ 9 μg/dL after administration of 250 mg of cosyntropin)

Patient satisfies criteria for severe sepsis Infection - one or more of the following criteria

  • Documented or Suspected - positive culture results (from blood, sputum, urine, etc.)
  • Anti-Infective Therapy - patient is receiving antibiotic, antifungal, or other anti-infective therapy
  • Pneumonia - documentation of pneumonia (x-ray, etc.)
  • WBCs - WBCs found in normally sterile .uid (urine, CSF, etc.)
  • Perforated Viscus - perforation of hollow organ (bowel)

SIRS - two or more of the following

  • Temperature > 38° or < 36°
  • Heart rate > 90 bpm
  • Respiratory rate above 20 breaths per minute
  • WBC > 14,000/mm3 , < 4000/mm3, or >10% Bands

Acute organ dysfunction - one or more of the following

  • Cardiovascular - SBP < 90 mmHg or MAP < 70 mmHg despite 20 mL/kg of fluid resuscitation
  • Respiratory - PaO2/FiO2 ratio < 250, PEEP > 7.5, or require mechanical ventilation
  • Renal - low urine output (eg, <0.5 mL/kg/hr for 1 hour despite 20mL/kg of fluid resuscitation, increased creatinine (>50% increase from baseline) or require acute dialysis
  • Hematologic - low platelet count (< 100,000/mm3) or PT/PTT > upper limit of normal
  • Metabolic - low pH with high lactate (eg, pH < 7.30 and plasma lactate > upper limit of normal
  • Hepatic - liver enzymes > 2x upper limit of normal
  • CNS - altered consciousness or reduced Glasgow Coma Score

Exclusion criteria

  • Patients who respond to the short cosyntropin stimulation test(Δ > 9mg/dL)
  • Pregnancy or breast-feeding mother
  • Evidence of acute myocardial infarction, meningitis, pulmonary embolism
  • AIDS (CD4 < 200 cells/mL)
  • Contraindications for corticosteroids
  • Formal indication for corticosteroids (specifically including patients with known adrenal insufficiency)
  • Onset of shock > 24 hours
  • Etomidate administration within the 6 hours preceding randomization
  • Cardiac arrest prior to randomization.

Treatment and study plan

Hydrocortisone

Drug

Hydrocortisone administered for the treatment of adrenal insufficiency in participants with severe sepsis.

fludrocortisone

Drug

Fludrocortisone administered in combination with hydrocortisone for the treatment of adrenal insufficiency in participants with severe sepsis.

Primary outcomes

  1. All cause mortality

    Time frame: 28 days

    All cause mortality during first 28-days after study randomization.

Secondary outcomes

  1. Intensive care unit survival, duration of intensive care unit stay, duration of hospitalization, survival to hospital discharge, time to vasopressor withdrawal

    Time frame: Unable to define

    The various secondary endpoints are patient specific serrogate markers of improvement in clinical status. Time frame for these endpoints to occur is patient specific and can not be defined for the entire study population.

Sponsors and collaborators

Lead sponsor

CAMC Health System

Other

Registry information

Official study title

A Blinded, Placebo Controlled Trial of Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Aug 24, 2006
Registry last updated
Aug 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.